Associate Professor of Medicine (Clin X)
To see if Brian Andrew Jonas is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Bone Marrow Transplant
2279 45th Street
Sacramento, CA 95817
Dr. Jonas believes in high quality, personalized, cutting edge, innovative, and compassionate care of his patients. Dr. Jonas has clinical trials that can offer new and progressive treatment options for his patients. Dr. Jonas believes in a team-based approach to patient care, utilizing expertise of nurse practitioners, nurses, pharmacists, social workers, and consultants to provide complete care for his patients.
Dr. Jonas is a specialist in hematologic malignancies, BMT and cellular therapy. His main clinical interests include: acute myeloid leukemia, myelodysplastic syndromes (MDS), acute lymphoblastic leukemia, myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes, CML, other myeloid malignancies.
Dr. Jonas specializes in acute myeloid leukemia, myelodysplastic syndromes (MDS), acute lymphoblastic leukemia, myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes, CML, other myeloid malignancies. Dr. Jonas directs the acute leukemia and MDS research efforts at UCDCCC. He has built a thematic clinical and translational research program in AML, MDS and ALL with an emphasis on early drug development and biomarker development and with a goal of having a clinical trial to offer each patient. He is also Chair of the UCDCCC Hematologic Malignancies Disease Team and is Chair of the UCDCCC Data and Safety Monitoring Committee.
Hematology and Oncology
B.A., Molecular & Cell Biology, History, UC Berkeley, Berkeley CA 1999
M.D., UC Davis School of Medicine, Davis CA 2007
Ph.D., Biochemistry and Molecular Biology, UC Davis School of Medicine, Davis CA 2007
Stanford Clinical Investigator Pathway, Stanford University School of Medicine, Stanford CA 2007-2008
Stanford Clinical Investigator Pathway, Stanford University School of Medicine, Stanford CA 2008-2009
Hematology and Oncology, Stanford University School of Medicine, Stanford CA 2009-2013
Highest Overall Accrual, UC Davis Comprehensive Cancer Center, 2020, 2021
NCI Cancer Center Support Grant Supplement Cancer Clinical Investigator Team Leadership Award, 2020
Highest Accrual, Hematologic Malignancies Clinical Trials, UC Davis Comprehensive Cancer Center, 2015, 2016, 2017, 2018, 2019, 2020, 2021
Named Sacramento Magazine Top Doctor Hematology/Oncology, 2018, 2019, 2020
Internal Medicine Outstanding Clinician Award, UC Davis Department of Internal Medicine, 2020
Jonas BA, Wei AH, Recher C, DiNardo CD, Jang JH, Pratz K, Panayiotidis P, Montesinos P, Yeh SP, Ivanov V, Fiedler W, Yamauchi T, Duan Y, Mendes W, Potluri J, Tews B, Ofran Y. Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 May 14. doi:10.1002/ajh.26600. Epub ahead of print. PMID:35567776.
Granowicz EM, Jonas BA. Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments. Onco Targets Ther. 2022 Apr 21;15:423-436. doi:10.2147/OTT.S265637. PMID:35479302.
Pratz KW, Panayiotidis P, Recher C, Wei X, Jonas BA, Montesinos P, Ivanov V, Schuh AC, DiNardo CD, Novak J, Pejsa V, Stevens D, Yeh SP, Kim I, Turgut M, Fracchiolla N, Yamamoto K, Ofran Y, Wei AH, Bui CN, Benjamin K, Kamalakar R, Potluri J, Mendes W, Devine J, Fiedler W. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer J. 2022 Apr 20;12(4):71. doi:10.1038/s41408-022-00668-8. PMID:35443742.
Kennedy VE, Hui G, Azenkot T, Gaut D, Wieduwilt MJ, Oliai C, Jonas BA, Mittal V, Logan AC, Muffly LS, Mannis GN. Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. Am J Hematol. 2022 Jun 1;97(6):E191-E194. doi:10.1002/ajh.26524. Epub 2022 Mar 18. PMID:35266185.
Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. J Natl Compr Canc Netw. 2022 Feb;20(2):106-117. doi:10.6004/jnccn.2022.0009. PMID:35130502.
Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, Döhner H. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. J Clin Oncol. 2022 Mar 10;40(8):855-865. doi:10.1200/JCO.21.01546. Epub 2021 Dec 15. PMID:34910556.
DeAngelo DJ, Jonas BA, Liesveld JL, Bixby DL, Advani AS, Marlton P, Magnani JL, Thackray HM, Feldman EJ, O'Dwyer ME, Becker PS. Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood. 2022 Feb 24;139(8):1135-1146. doi:10.1182/blood.2021010721. PMID:34543383.
Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM. Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. Leuk Lymphoma. 2022 Jan;63(1):231-234. doi:10.1080/10428194.2021.1975190. Epub 2021 Sep 6. PMID:34486920.
Othman TA, Tenold ME, Moskoff BN, Azenkot T, Jonas BA. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia. Expert Rev Hematol. 2021 May;14(5):407-417. doi:10.1080/17474086.2021.1938533. Epub 2021 Jun 15. PMID:34076549.